Helus Pharma Inc.
HELP · NEO · Healthcare / Biotechnology
Price History
Full chartMarket Stats
About
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Michael I. Halstead J.D.
- Employees100
- Headquarters100 King Street West, Toronto, ON, Canada, M5X 1C9, Canada
- Websitehttps://www.helus.com
Leadership
- Mr. Eric So L.L.B.Co-Founder, President & Executive Chairman · b. 1976
- Mr. Paul GlavineCo-Founder, Chief Growth Officer & Director · b. 1989
- Mr. Greg CaversChief Financial Officer · b. 1971
- Mr. Aaron BartloneChief Operating Officer · b. 1967
- Dr. Amir Inamdar FFPM, MBBSChief Medical Officer · b. 1974
- Mr. Michael I. Halstead J.D.CEO & Director · b. 1973
- Mr. John KanakisCo-Founder · b. 1980
- Dr. Alex L. Nivorozhkin Ph.D.Chief Scientific Officer · b. 1960
- Ms. Lori ChallengerChief Compliance, Ethics & Administrative Officer
- Mr. Gabriel FahelChief Legal Officer & Corporate Secretary · b. 1976
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Stock Splits
- Sep 19, 20241:38